Although oral contraceptives are protective for ovarian cancer, it is unclear how long this protection persists. The authors prospectively assessed this question as well as associations of other, less studied contraceptive methods (tubal ligation, rhythm method, diaphragm, condoms, intrauterine device, foam, spousal vasectomy) and infertility with ovarian cancer risk among 107,900 participants in the US Nurses' Health Study. During 28 years of follow-up (1976-2004), 612 cases of invasive epithelial ovarian cancer were confirmed. Duration of oral contraceptive use was inversely associated with risk (p-trend ¼ 0.02), but no clear trend was observed for years since last use. However, for women using oral contraceptives for >5 years, the rate ratio for ovarian cancer for 20 years since last use was 0.58 (95% confidence interval (CI): 0.39, 0.87), with no association found for >20 years since last use (rate ratio (RR) ¼ 0.92, 95% CI: 0.61, 1.39). Tubal ligation (RR ¼ 0.66, 95% CI: 0.50, 0.87) was associated with decreased ovarian cancer risk, whereas intrauterine device use (RR ¼ 1.76, 95% CI: 1.08, 2.85) and infertility (RR ¼ 1.36, 95% CI: 1.07, 1.75) were associated with an increased risk. Results suggest that the beneficial effect of oral contraceptives on ovarian cancer risk attenuates after 20 years since last use. Furthermore, tubal ligation, intrauterine device use, and infertility were associated with ovarian cancer risk.
little is known about other contraceptive methods and risk of ovarian cancer, with one study reporting a decreased risk of ovarian cancer associated with several contraceptive methods among parous women (26) . Furthermore, female-related infertility may increase risk of ovarian cancer (7, 15, 21, (27) (28) (29) (30) (31) .
We examined ovarian cancer risk in relation to duration and time since last oral contraceptive use, and in relation to other contraceptive methods and infertility among participants in the Nurses' Health Study. To our knowledge, this is the longest prospective cohort study of incident ovarian cancer, with 28 years of follow-up, published to date.
MATERIALS AND METHODS

Study population
In 1976, 121,700 US married, female registered nurses, aged 30-55 years, completed a mailed questionnaire on their history of oral contraceptive use and known or suspected risk factors for cancer (32) (33) (34) (35) . Follow-up questionnaires were mailed biennially to update information on risk factors and newly diagnosed diseases. The follow-up rate for the cohort through May 31, 2004 , was 95 percent of the potential person-years.
Ascertainment of ovarian cancer cases
Incident cases of epithelial ovarian cancer were identified by biennial questionnaire from 1976 to 2004. For women reporting a new ovarian cancer or cases identified via death certificate (35) , we obtained pathology reports and related medical records. A gynecologic pathologist, unaware of exposure status, reviewed the records to confirm the diagnosis and identify histologic type, subtype, morphology, and stage. We compared the histologic type abstracted from the pathology report with a standardized review of pathology slides completed by a gynecologic pathologist for a subset of 215 ovarian cancer cases. Overall, the concordance for invasiveness was 98 percent and for histologic type was 83 percent; histologic type was used from the medical record review for all cases.
Assessment of contraceptive use, infertility, and other covariates
In 1976, cohort participants were asked to indicate the intervals of oral contraceptive use, starting with their first use to the present time. Regular oral contraceptive use was queried biennially from 1978 to 1984, after which use became rare because of the age of the cohort. We calculated total duration of oral contraceptive use and determined years since last use. We also examined years since last use of oral contraceptives (20 vs. >20 years) among women who used oral contraceptives for 5 versus >5 years.
We ascertained use of other contraceptive methods, including tubal ligation, rhythm method, diaphragm, condoms, intrauterine device (IUD), foam, and spousal vasectomy, on each biennial questionnaire from 1976 (among premenopausal women only) to 1982. Tubal ligation history was queried again in 1994.
We assessed infertility in 1980 by asking about attempts to become pregnant for >2 years without success. Those replying affirmatively were asked whether a cause was due to themselves, their spouse, or unknown. We did not collect information about treatment for infertility until 1992, and, because use was minimal, we did not evaluate this factor.
Age, calculated from date of birth to date of questionnaire return, was updated biennially. We queried women about age at menarche; height; age at natural menopause; use of postmenopausal hormones, including duration; smoking history; and weight in 1976, and all but age at menarche and height were asked biennially thereafter. Weight at age 18 years was assessed in 1980. Parity, defined as number of pregnancies lasting at least 6 months, was queried from 1976 to 1984. We queried women about history of menstrual irregularity in 1982 and family history of ovarian cancer in 1992.
Exclusions
We excluded the following women at baseline: those reporting any diagnosis of cancer besides nonmelanoma skin cancer (n ¼ 3,359), those with a history of bilateral oophorectomy (n ¼ 7,665), those with a history of pelvic irradiation (n ¼ 99), and women reporting no year of birth (n ¼ 123). We previously reported 97 percent agreement between self-reported surgical menopause and medical records (22) . After exclusions, 107,900 women remained in the analysis at the start of follow-up. Exclusions were updated biennially.
Statistical analysis
We calculated person-years from the 1976 questionnaire return date to date of ovarian cancer diagnosis, death, or May 31, 2004 , whichever occurred sooner. Incidence rates for each category of oral contraceptive use were calculated by dividing the number of incident ovarian cancer cases by the total person-time in that category. Cox regression with time-dependent covariates was used to estimate rate ratios and 95 percent confidence intervals; women who never used oral contraceptives were considered the reference. We adjusted for age, current body mass index, body mass index at age 18 years, parity, duration of postmenopausal hormone use, history of tubal ligation, smoking, and ages at menarche and menopause. In models examining years since last oral contraceptive use and other forms of contraception, we additionally controlled for duration of oral contraceptive use. Models for infertility were adjusted for age, duration of oral contraceptive use, current body mass index, body mass index at age 18 years, duration of postmenopausal hormone use, smoking, and ages at menarche and menopause (but not parity or tubal ligation).
We used interaction terms and stratified analyses to assess effect modification by use of postmenopausal hormones and smoking (never/past vs. current); tubal ligation and menstrual cycle regularity (yes vs. no); parity (0 vs. 1 children); current body mass index and body mass index at age 18 years (<25 vs. 25 kg/m 2 ); and menopausal status (premenopausal vs. postmenopausal).
We considered invasive epithelial cancers in our main analyses. However, we also evaluated risk of invasive and borderline tumors together, borderline tumors separately, and risk of the major subtypes of ovarian cancer (serous/ poorly differentiated, endometrioid, mucinous).
RESULTS
During 28 years of follow-up, we accrued 2,479,493 person-years from 107,900 women and identified 1,243 potential cases of ovarian cancer; 82 percent were selfreported and 18 percent were identified by death certificate. Of these, we did not confirm ovarian cancer for 236 (19 percent) women (the woman denied the diagnosis or the woman had a different type of cancer, had a metastasis from another primary site, or did not have cancer upon medical record review). We were unable to obtain medical records for 146 (12 percent) women. Of the 861 confirmed cases, 769 (89 percent) were primary epithelial ovarian cancers; after excluding women with a diagnosis of another cancer (except nonmelanoma skin cancer) prior to their ovarian cancer diagnosis and those for whom information on oral contraceptive duration was missing, 612 invasive cases (plus 75 borderline, 2 of unknown morphology) were available for analysis.
Compared with women who had never used oral contraceptives, women reporting >10 years of use as of 1990 (the midpoint of the study) were more likely to be parous, to be currently using postmenopausal hormones, and to have a history of tubal ligation (table 1) . In general, other potential risk factors, including family history of ovarian cancer, were similar by oral contraceptive use.
Increasing duration of oral contraceptive use was associated with decreasing ovarian cancer risk (multivariate rate ratio (RR) for >5-10 years vs. never ¼ 0.75, 95 percent confidence interval (CI): 0.54, 1.05, and RR for >10 years ¼ 0.62, 95 percent CI: 0.37, 1.04; p-trend ¼ 0.02) (table 2). We did not observe a trend across time since last use (p-trend ¼ 0.57), although women with 5-<10 years since last use had a significantly lower risk compared with nonusers (RR ¼ 0.53, 95 percent CI: 0.30, 0.94). This association was substantially attenuated after adjustment for duration of oral contraceptive use (data not shown). We also stratified duration of oral contraceptive use by time since last use (p-interaction ¼ 0.65). Among women who used oral contraceptives for 5 years, we observed an inverse association for only those reporting 20 years since last use (RR ¼ 0.58, 95 percent CI: 0.39, 0.87; p ¼ 0.008); this risk estimate was nearly statistically significantly different (p ¼ 0.11) from that for women reporting >20 years since last use (RR ¼ 0.92, 95 percent CI: 0.61, 1.39; p ¼ 0.69). We observed no associations for women with 5 years duration of use. Neither age at first nor at last oral contraceptive use was associated with ovarian cancer risk after adjusting for duration of use (data not shown).
The results generally were similar when including borderline cases (n ¼ 689 cases in total), although the rate ratio for >10 years of use was somewhat attenuated (RR ¼ 0. ) . In this older population, we observed that no contraceptive method of any kind was used for 37 percent of person-years. When we used this population as the reference group, the results were similar for other contraceptive methods (data not shown).
Women who reported attempting to become pregnant for at least 2 years without a success (and without a known male factor infertility) were at slightly increased risk of ovarian cancer (RR ¼ 1.36, 95 percent CI: 1.07, 1.75; p ¼ 0.01) relative to those without such a history. Results were similar among nulliparous and parous women (data not shown).
DISCUSSION
To our knowledge, this is the largest prospective study examining the relation between contraceptive methods or infertility and risk of incident ovarian cancer. The inverse association between long-term oral contraceptive use and risk of invasive epithelial ovarian cancer appeared to attenuate with longer time since last use. In addition, we observed a strong inverse relation between tubal ligation and ovarian cancer risk, and a positive association with IUD use. A modest positive association was found for infertility.
We observed a 38 percent reduction in incident ovarian cancer risk with 10 years of oral contraceptive use. This association is somewhat smaller in magnitude than that observed in previous case-control studies (11, 26, 36) , two prospective studies of ovarian cancer death (10, 37) , and one prospective study of ovarian cancer incidence (38) , which suggested a 50-80 percent decreased risk with 10 years of use. Differences between our study and previous prospective studies may be that our population was older on average. Furthermore, given the apparent trend of waning protection with increased time since last use (no association after >20 years) and the very long follow-up time in our study (28 years), the association likely would be weaker than in studies with younger women or a shorter followup time. In fact, when we excluded the last 4 years of follow-up from our analysis, the relative risk for >10 years of oral contraceptive use decreased to 0.48 (95 percent CI: 0.24, 0.93).
Although we did not observe a clear trend for time since last oral contraceptive use either before or after adjustment for duration of use, there did not appear to be a protective effect after 20 years of use. In general, prospective studies of incidence or mortality have observed at least some attenuation in the association after 20 years since last use (10, 37, 38) . Case-control studies have been inconsistent, with suggestions of an effect after 20-29 years since last use (9, 39, 40) to a strong attenuation of the effect within 20-25 years since last use (28, 36, 41) . Differences could be due to the age and length of follow-up of study subjects, because younger populations may have a shorter mean time since last use within categories.
Furthermore, women reporting a longer time since last use may have a shorter duration on average than those with a shorter time since last use. To separate these effects, we stratified time since last use by duration and observed a protective effect of oral contraceptives for only those women reporting a long duration (>5 years) and 20 years since last use, suggesting that, even among women with a longer duration of use, the protective effect decreases over time. This finding was not due to differences in duration between long-term oral contraceptive users who reported 20 years (mean duration, 107 months) versus >20 years since last use (mean duration, 100 months). Since oral contraceptives are usually taken in young adulthood but ovarian cancer incidence peaks after menopause, women may not maintain the protective effect of oral contraceptive use to the time of highest incidence.
We observed an association between oral contraceptive use and invasive ovarian cancer risk, but not with borderline tumors. This finding is consistent with some (28, 38, 42), but not all (9, 25, 40) , studies. Only one other prospective study is known to have separated borderline and invasive tumors, observing a nonsignificant inverse association for the former and a significant inverse association for the latter (38) . Given the small number of borderline tumors in each individual study and the large heterogeneity in results, the association between oral contraceptive use and borderline tumors is unclear. However, one potential explanation for our results is that the latency of borderline tumors appears to be shorter (about 10-15 years) than that of invasive tumors (43) . Since our population is older, borderline tumors may have developed in the postmenopausal years when the protective effect of oral contraceptives on risk was waning (42) . Interestingly, however, our study and most previous studies (9, 25, 40, 44) have reported that oral contraceptive use is similarly associated with most ovarian cancer subtypes, suggesting a common underlying etiologic pathway for the effect of oral contraceptives on ovarian carcinogenesis.
We also observed that tubal ligation was inversely associated with ovarian cancer risk. This finding is consistent with previous studies (7, 22, 24, 26, 45, 46) . Although the underlying biologic mechanisms are not well understood, epidemiologic evidence strongly supports a causal relation between tubal ligation and lower ovarian cancer risk. It will be important to determine the associations by type of and time since tubal ligation with ovarian cancer risk in future studies.
Less is known about whether other contraceptive methods are associated with ovarian cancer risk. Ness et al. (26) reported that all methods of contraception conferred a decreased risk of ovarian cancer. The authors suggested that any use of contraception was a surrogate for fertility, which may be the underlying exposure of interest (26) . However, in our study, we did not observe associations between most forms of contraception and risk of ovarian cancer. This difference possibly may be due to selection or recall bias in the case-control study. Interestingly, we observed an increased risk of invasive epithelial ovarian cancer with self-reported IUD use, which conflicts with an inverse association observed by two case-control studies (26, 47) . It is possible that IUD use increases inflammation in the peritoneal cavity (47) , thereby increasing ovarian cancer risk. However, most IUD use in our study was in the 1970s-1980s; our risk estimate may not reflect that for newer IUDs. Clearly, further research should examine the relation between various contraceptive methods and risk of ovarian cancer, particularly because these behaviors are modifiable.
Recently, several studies examined the risk of ovarian cancer for women reporting female-related infertility (7, 15, 21, (27) (28) (29) (30) (31) . In general, these studies, as well as our own, reported either no association or a modestly increased risk for infertile women. Lack of observed associations may be due to small sample sizes, since the association, if any exists, appears to be modest. We were unable to assess use of infertility drugs in this analysis because use of these agents was minimal and not queried until 1992; therefore, we cannot determine whether the apparent increase in risk is due to infertility itself or treatment of infertility.
Specific strengths of our study include multiple, prospective ascertainments of contraceptive methods among a large cohort of women, with detailed reporting on other reproductive factors, and a long follow-up period. Having multiple measures minimizes the potential impact of measurement error and enabled us to assess duration of use for periods of time >10 years and time since last use for >30 years. Because some women may shift between various contraceptive methods, having repeated assessments of contraceptive methods is important. Potential limitations of the study include the possibility of error in self-reported contraceptive use, although it would generally bias results toward the null. Another potential limitation is our inability to control for family history in our main analyses. However, family history varied little by oral contraceptive use, suggesting that it is not a strong confounder. We also did not have detailed information about infertility and its treatment, limiting interpretation of this analysis.
In summary, we observed that the protective effect of long duration of oral contraceptive use waned after 20 years since last use. Among other contraceptive methods, most were not associated with risk, with the exception of tubal ligation (inverse association) and IUD use (positive association). History of infertility was associated with a modestly increased risk of ovarian cancer. Oral contraceptives are the only known chemoprotective agent for ovarian cancer. Future studies should continue to examine the potential waning effect of oral contraceptives with longer time since last use, as well as continue to explore potential associations with other contraceptive methods and infertility. ), parity (continuous), history of tubal ligation (ever/never), smoking history (never, current, past), age at menarche (<11, 11, 12, 13 years), age at menopause (premenopausal, <45, 45-49, 50-52, 53-54, 55 years), duration of postmenopausal hormone use (continuous), and duration of oral contraceptive use (continuous).
y Only premenopausal women were queried as to other contraceptives used in 1976. z RR, rate ratio; CI, confidence interval; ref, referent; IUD, intrauterine device. § Referent group includes both women using other methods and women who reported not practicing any contraceptive method.
{ Data were not collected about infertility until 1980, which was the baseline year for this analysis. Adjusted for age (continuous), duration of oral contraceptive use (continuous), body mass index (<21, 21-<23, 23-<25, 25-<30, 30 kg/m
